Study | Number of serious adverse events reported n/N (%) | Description |
Mbrenga 2022 | 1/14 (7%) | Case 1: life‐threatening anaemia at day 9. Also positive for malaria and HIV. |
Total | 1/14 (7%) |
Study | Number of serious adverse events reported n/N (%) | Description |
Mbrenga 2022 | 1/14 (7%) | Case 1: life‐threatening anaemia at day 9. Also positive for malaria and HIV. |
Total | 1/14 (7%) |